<DOC>
	<DOCNO>NCT01196234</DOCNO>
	<brief_summary>This study compare paclitaxel/carboplatin ( PC ) PC chemotherapy follow gefitinib 2 week patient Non-small Cell Lung Cancer ( NSCLC ) without epidermal growth factor receptor ( EGFR ) mutation . Expanded acronym : [ P ] aclitaxel/Ca [ r ] boplatin ( PC ) follow Gef [ ] tinib A [ ] vanc [ e ] Non-small Cell Lung Cancer ( NSCLC ) : Randomized phase II study .</brief_summary>
	<brief_title>Paclitaxel/Carboplatin ( PC ) Followed Gefitinib Versus PC Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>A randomized phase II trial compare paclitaxel/carboplatin ( PC ) PC chemotherapy follow gefitinib 2 week patient NSCLC without EGFR mutation . While previous study cytotoxic agent gefitinib fail show benefit , alter schedule administration hop gain synergy agent .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>More 18 year age Histologically document nonsmall cell lung cancer metastasis ( Stage IV ) locally advanced ( Stage IIIB ) malignant effusion . At least 1 measurable lesion define RECIST1.0 . All target lesion must unidirectional diameter least 1cm . Baseline measurement must compare within 4 week prior enrollment . ECOG PS 02 At least 1 week since last radiotherapy . Patients must recover acute toxicity radiotherapy . Patients must adequate hematologic , renal liver function define Hb &gt; 9g/dL , neutrophil &gt; 1000/mm3 , platelet &gt; 50,000/mm3 , creatinine &lt; 2mg/dL , AST ( SGOT ) and/or ALT ( SGPT ) &lt; 5 x UNL ( upper normal limit ) . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Written voluntary inform consent understood , sign date . Patients tumor harbor EGFR mutation . Prior systemic therapy NSCLC Nonsmoking patient adenocarcinoma . But patient show wild type EGFR , eligible study . Symptomatic brain metastasis . Brain metastases stable &lt; 2 week dose require concurrent steroid treatment clinical symptom . Major surgery within 3 week prior study enrollment . Previous ( less 3 year ago ) current malignancy sit curatively treat situ carcinoma cervix , basal squamous cell carcinoma skin . Severe medical illness active infection would impair ability receive gefitinib . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>